SDC1 and plasma cell myeloma: In an independent experiment, we confirmed that treatment with two doses of either CAR-T cells from a different donor evoke the remarkable anti-tumor efficacy (Supplementary Fig. 7a–d), and flow cytometric analysis of the mononuclear cells in the peripheral blood, spine as well as bone marrow of the mice showed that human CD138+ myeloma cells were almost eliminated while human CD3+ T cells were evidently present at these sites three weeks following treatment (Supplementary Fig. 7e, f).